Guidelines on Benefit-Risk Assessment for New Drug Development – Draft for Comments

On December 13, 2024, the Center for Drug Evaluation (CDE) of China released a draft of the Guidelines for Benefit-Risk Assessment Based on Multi-Regional Clinical Trial Data in Global Simultaneous Development of New Drugs for public consultation.These guidelines aim to support pharmaceutical companies in integrating multi-regional clinical trial (MRCT) data into benefit-risk assessments, aligning China’s regulatory framework with international standards.

Overview of Guidelines on Benefit-Risk Assessment

The guidelines provide a structured approach to evaluating benefit-risk profiles for new drugs developed across multiple regions. They emphasize flexibility in assessment methods, integration of diverse data sources, and consideration of regional differences in disease characteristics and patient demographics.

1) Incorporating Global Data in Benefit-risk Assessments

The guidelines underscore the importance of harmonizing clinical trial data across different regions to ensure comprehensive evaluations. While discussing intrinsic and extrinsic factors—such as genetics, physiology, and healthcare practices—that may influence drug responses, the document remains high-level in its approach to defining specific population subgroups.

2) Flexible Assessment Methods for Emerging Therapies

The CDE encourages the use of model-informed drug development (MIDD) tools to support benefit-risk assessments, particularly for innovative therapies. The guidance is designed to be broadly applicable, allowing for flexibility in adapting these methods to different treatment areas.

3) Early-stage Data Integration for Accelerated Development

The guidelines highlight the value of incorporating early-stage Chinese clinical data to strengthen global drug development strategies. This approach is particularly relevant for therapies targeting diseases with a notable presence in China, though the document does not specify threshold criteria for defining a "significant local patient base."

4) Optimizing Study Design to Address Regional Variability

Recognizing that disease characteristics and treatment practices vary across regions, the guidelines encourage study designs that accommodate these differences. While no specific diseases are listed, the principles outlined can be adapted to a wide range of therapeutic areas.

5) Use of Real-world Evidence (RWE)

Acknowledging the growing role of real-world evidence (RWE) in regulatory decision-making, the guidelines encourage its integration into benefit-risk assessments. The application of RWE is positioned as a complementary tool to traditional clinical trials, enhancing the robustness of evaluations.

How to Submit Comments

Stakeholders, including pharmaceutical companies and healthcare professionals, are encouraged to submit their feedback to the CDE by emailing official comments to wangyzh@cde.org.cn and majy@cde.org.cn by February 12, 2025.

Conclusion

By promoting a structured yet adaptable framework for benefit-risk assessments, the guidelines seek to enhance regulatory efficiency and facilitate global drug development.Their emphasis on flexibility and broad applicability provides a foundation for companies navigating multi-regional clinical trials, with room for further refinement based on stakeholder feedback.

Further Information

To read the draft of the Guidelines for Benefit-Risk Assessment Based on Multi-Regional Clinical Trial Data in Global Simultaneous Development of New Drugs published by the CDE, please click here

GET IN TOUCH

🌐 Send us your enquiry📚 Request our whitepapers📣 Sign up for our newsletter